Skip to main content

Advertisement

Table 2 Relationships between clinicopathological characteristics and pathological response evaluated by Mandard-TRG system

From: Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China

Characteristics Total cases (n = 192), no. (%) Mandard-TRG P value
1 (n = 11), no. (%) 2 (n = 23), no. (%) 3 (n = 40), no. (%) 4 (n = 78), no. (%) 5 (n = 40), no. (%)
Gender        0.039
 Male 139 (72.4) 10 (7.2) 20 (14.4) 29 (20.9) 48 (34.5) 32 (23)  
 Female 53 (27.6) 1 (1.9) 3 (5.7) 11 (20.8) 30 (56.6) 8 (15.1)  
Age        0.867
 < 55y 89 (46.4) 6 (6.7) 10 (11.2) 17 (19.1) 39 (43.8) 17 (19.1)  
 ≥ 55y 103 (53.6) 5 (4.9) 13 (12.6) 23 (22.3) 39 (37.9) 23 (22.3)  
Location        0.351
 Esophagogastric junction 44 (22.9) 1 (2.3) 4 (9.1) 8 (18.2) 20 (45.5) 11 (25)  
 Proximal gastric 71 (37) 7 (9.9) 8 (11.3) 15 (21.1) 23 (32.4) 18 (25.4)  
 Distal gastric 77 (40.1) 3 (3.9) 11 (14.3) 17 (22.1) 35 (45.5) 11 (14.3)  
Maximal diameter of tumor bed        0.004
 < 4.5 cm 108 (56.2) 9 (8.3) 20 (18.5) 20 (18.5) 44 (40.7) 15 (13.9)  
 4.5–8 cm 64 (33.3) 1 (1.6) 3 (4.7) 17 (26.6) 27 (42.2) 16 (25)  
 > 8 cm 20 (10.4) 1 (5) 0 (0) 3 (15) 7 (35) 9 (45)  
Histological differentiation        0.003
 Well-moderate 45 (23.4) 4 (8.9) 12 (26.7) 9 (20) 16 (35.6) 4 (8.9)  
 Poor 147 (76.6) 7 (4.8) 11 (7.5) 31 (21.1) 62 (42.2) 36 (24.5)  
Laurén classification        0.240
 Intestinal 77 (40.1) 4 (5.2) 14 (18.2) 14 (19.2) 28 (36.4) 15 (19.5)  
 Diffuse 73 (38) 7 (9.6) 5 (6.8) 10 (23.8) 33 (45.2) 14 (19.2)  
 Mixed 42 (21.9) 0 (0) 4 (9.5) 15 (35.7) 17 (40.5) 11 (26.2)  
LVI        <0.001
 Negative 94 (49) 11 (11.7) 19 (20.2) 28 (29.8) 26 (27.7) 10 (10.6)  
 Positive 98 (51) 0 (0) 4 (4.1) 12 (12.2) 52 (53.1) 30 (30.6)  
PNI        <0.001
 Negative 76 (39.6) 11 (14.5) 22 (28.9) 13 (17.1) 23 (30.3) 7 (9.2)  
 Positive 116 (60.4) 0 (0) 1 (0.9) 27 (23.3) 55 (47.4) 33 (28.4)  
AJCC ypT category        <0.001
 0 11 (5.7) 11 (100) 0 (0) 0 (0) 0 (0) 0 (0)  
 1 20 (10.4) 0 (0) 12 (60) 5 (25) 3 (15) 0 (0)  
 2 23 (12) 0 (0) 5 (21.7) 6 (26.1) 12 (52.2) 0 (0)  
 3 57 (29.7) 0 (0) 5 (8.8) 18 (31.6) 25 (43.9) 9 (15.8)  
 4 81 (42.2) 0 (0) 1 (1.2) 11 (13.6) 38 (46.9) 31 (38.3)  
AJCC ypN category        <0.001
 0 55 (28.6) 9 (16.4) 13 (23.6) 17 (30.9) 10 (18.2) 6 (10.9)  
 1 36 (18.8) 0 (0) 6 (16.7) 7 (19.4) 16 (44.4) 7 (19.4)  
 2 50 (26) 0 (0) 3 (6) 10 (20) 32 (64) 5 (10)  
 3 51 (26.6) 2 (3.9) 1 (2) 6 (11.8) 20 (39.2) 22 (43.1)  
AJCC stage        <0.001
 0 9 (4.7) 9 (100) 0 (0) 0 (0) 0 (0) 0 (0)  
 1 24 (12.5) 0 (0) 14 (58.3) 7 (29.2) 2 (8.3) 1 (4.2)  
 2 53 (27.6) 2 (3.8) 6 (11.3) 14 (26.4) 21 (39.6) 10 (18.9)  
 3 106 (55.2) 0 (0) 3 (2.8) 19 (17.9) 55 (51.9) 29 (27.4)  
R0 resection        0.185
 Yes 159 (82.8) 11 (6.9) 20 (12.6) 35 (22) 64 (40.3) 29 (18.2)  
 No 33 (17.2) 0 (0) 3 (9.1) 5 (15.2) 14 (42.4) 11 (33.3)  
Adjuvant chemotherapy        0.766
 Not received 59 (30.7) 3 (5.1) 6 (10.2) 10 (16.9) 25 (42.4) 15 (25.4)  
 Received 133 (69.3) 8 (6) 17 (12.8) 30 (22.6) 53 (39.8) 25 (18.8)